Chlorin e6 and BLZ945 Based Self-Assembly for Photodynamic Immunotherapy Through Immunogenic Tumor Induction and Tumor-Associated Macrophage Depletion

被引:1
作者
Huang, Chu-Yu [1 ,2 ]
Zhao, Lin-Ping [1 ,2 ]
Rao, Xiao-Na [1 ,2 ]
Zheng, Rong-Rong [1 ,2 ]
Liu, Zhi-Shan [1 ,2 ]
Cai, Hua [3 ,4 ]
Zhang, Wei [5 ]
Chen, A-Li [5 ]
Xu, Lin [3 ,4 ]
Li, Shiying [1 ,2 ]
机构
[1] Guangzhou Med Univ, Affiliated Hosp 5, Sch Pharmaceut Sci, Guangdong Prov Key Lab Mol Target & Clin Pharmacol, Guangzhou 511436, Peoples R China
[2] Guangzhou Med Univ, Sch Pharmaceut Sci, State Key Lab Resp Dis, Guangzhou 511436, Peoples R China
[3] Peoples Liberat Army PLA, Gen Hosp Southern Theatre Command, Dept Geriatr Cardiol, Guangzhou 510016, Peoples R China
[4] Guangdong Pharmaceut Univ, Guangzhou 510016, Peoples R China
[5] Guangdong Pharmaceut Univ, Ctr Drug Res & Dev, Guangdong Prov Key Lab Adv Drug Delivery Syst, Guangzhou 510006, Peoples R China
基金
国家重点研发计划; 中国国家自然科学基金;
关键词
colony stimulating factor 1 receptor (CSF-1R); drug self-assembly; immunogenic induction; photodynamic therapy; tumor-associated macrophages; NANOMEDICINES;
D O I
10.1002/adhm.202304576
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Immunotherapeutic effect is restricted by the nonimmunogenic tumor phenotype and immunosuppression behaviors of tumor-associated macrophages (TAMs). In this work, a drug self-assembly (designated as CeBLZ) is fabricated based on chlorin e6 (Ce6) and BLZ945 to activate photodynamic immunotherapy through tumor immunogenic induction and tumor-associated macrophage depletion. It is found that Ce6 tends to assemble with BLZ945 without any drug excipients, which can enhance the cellular uptake, tumor penetration, and blood circulation behaviors. The robust photodynamic therapy effect of CeBLZ efficiently suppresses the primary tumor growth and also triggers immunogenic cell death to reverse the nonimmunogenic tumor phenotype. Moreover, CeBLZ can deplete TAMs in tumor tissues to reverse the immunosuppression microenvironment, activating abscopal effect for distant tumor inhibition. In vitro and in vivo results confirm the superior antitumor effect of CeBLZ with negligible side effect, which might promote the development of sophisticated drug combinations for systematic tumor management. A drug self-assembly based on Chlorin e6 and BLZ945 is developed to improve the drug stability and delivery efficiency, which can enhance photodynamic immunotherapy through tumor immunogenic induction and tumor-associated macrophage depletion. The self-assembled drug delivery system not only promotes the primary tumor eradication but also improves immunosuppression microenvironments to activate abscopal effect for distant tumor suppression. image
引用
收藏
页数:14
相关论文
共 36 条
  • [21] Overcoming Limitations in Nanoparticle Drug Delivery: Triggered, Intravascular Release to Improve Drug Penetration into Tumors
    Manzoor, Ashley A.
    Lindner, Lars H.
    Landon, Chelsea D.
    Park, Ji-Young
    Simnick, Andrew J.
    Dreher, Matthew R.
    Das, Shiva
    Hanna, Gabi
    Park, Won
    Chilkoti, Ashutosh
    Koning, Gerben A.
    ten Hagen, Timo L. M.
    Needham, David
    Dewhirst, Mark W.
    [J]. CANCER RESEARCH, 2012, 72 (21) : 5566 - 5575
  • [22] Roles for macrophage-polarizing interleukins in cancer immunity and immunotherapy
    Mortezaee, Keywan
    Majidpoor, Jamal
    [J]. CELLULAR ONCOLOGY, 2022, 45 (03) : 333 - 353
  • [23] Manipulation of the tumor immuno-microenvironment via TAM-targeted expression of transcription factors
    Musick, Maggie
    Yu, Xianzhong
    [J]. IMMUNOLOGIC RESEARCH, 2022, 70 (04) : 432 - 440
  • [24] Evolution of drug delivery systems: From 1950 to 2020 and beyond
    Park, Haesun
    Otte, Andrew
    Park, Kinam
    [J]. JOURNAL OF CONTROLLED RELEASE, 2022, 342 : 53 - 65
  • [25] Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy
    Ries, Carola H.
    Cannarile, Michael A.
    Hoves, Sabine
    Benz, Joerg
    Wartha, Katharina
    Runza, Valeria
    Rey-Giraud, Flora
    Pradel, Leon P.
    Feuerhake, Friedrich
    Klaman, Irina
    Jones, Tobin
    Jucknischke, Ute
    Scheiblich, Stefan
    Kaluza, Klaus
    Gorr, Ingo H.
    Walz, Antje
    Abiraj, Keelara
    Cassier, Philippe A.
    Sica, Antonio
    Gomez-Roca, Carlos
    de Visser, Karin E.
    Italiano, Antoine
    Le Tourneau, Christophe
    Delord, Jean-Pierre
    Levitsky, Hyam
    Blay, Jean-Yves
    Ruettinger, Dominik
    [J]. CANCER CELL, 2014, 25 (06) : 846 - 859
  • [26] Novel CSF1R-positive tenosynovial giant cell tumor cell lines and their pexidartinib (PLX3397) and sotuletinib (BLZ945)-induced apoptosis
    Thongchot, Suyanee
    Duangkaew, Supani
    Yotchai, Wasan
    Maungsomboon, Sorranart
    Phimolsarnti, Rapin
    Asavamongkolkul, Apichat
    Thuwajit, Peti
    Thuwajit, Chanitra
    Chandhanayingyong, Chandhanarat
    [J]. HUMAN CELL, 2023, 36 (01) : 456 - 467
  • [27] Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response
    Wang, Dong-Rui
    Wu, Xian-Lin
    Sun, Ying-Li
    [J]. SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2022, 7 (01)
  • [28] Activating Nanomedicines with Electromagnetic Energy for Deep-Tissue Induction of Immunogenic Cell Death in Cancer Immunotherapy
    Wang, Fengshuo
    Pu, Kanyi
    Li, Jingchao
    [J]. SMALL METHODS, 2023, 7 (05)
  • [29] Nanoparticle-mediated synergistic anticancer effect of ferroptosis and photodynamic therapy: Novel insights and perspectives
    Wang, Haiying
    Qiao, Chu
    Guan, Qiutong
    Wei, Minjie
    Li, Zhenhua
    [J]. ASIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2023, 18 (04)
  • [30] Thymosin a-1 Reverses M2 Polarization of Tumor-Associated Macrophages during Efferocytosis
    Wei, Yi-ting
    Wang, Xu-ru
    Yan, Chunguang
    Huang, Fang
    Zhang, Yunpeng
    Liu, Xueming
    Wen, Zhi-fa
    Sun, Xiao-tong
    Zhang, Yue
    Chen, Yong-qiang
    Gao, Rong
    Pan, Ning
    Wang, Li-xin
    [J]. CANCER RESEARCH, 2022, 82 (10) : 1991 - 2002